UNSPSC 51384621: Aminophenazone cyclamate

This classification denotes an analgesic and antipyretic with the molecular formula C13H17N3O.C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM5BP192F9, chemically known as 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one cyclohexylsulfamate but more generally known as aminophenazone cyclamate, which bears US NIH Compound Identifier 170322. European Medicines Agency schedules Aminophenazone cyclamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05443MIG.

UNSPSC 51384621 Aminophenazone cyclamate, a Commodity code, shows misalignment between its nominal scope and recent state and local procurement activity. The three recent opportunities tagged under this code—naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy program inquiry, and generic multi-source pharmaceuticals and OTC products—do not involve aminophenazone cyclamate or related analgesic compounds. The code appears to capture pharmaceutical procurement across health departments and cooperative purchasing alliances, but the actual work solicited spans emergency response medications, pharmacy benefit program restructuring, and broad-based generic drug distribution contracts rather than the specific active ingredient this commodity code nominally identifies. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing organizations administering on behalf of participating state and local government facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023—a date discrepancy in the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, requiring E-Verify compliance and standard insurance coverage. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, released an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract awards effective July 1, 2026 and a 3 percent administrative fee requirement. None of these solicitations appear to involve aminophenazone cyclamate specifically, suggesting either misclassification or significant divergence between the code's intended scope and current purchasing practice.